Natera, Inc. $NTRA Shares Sold by Ramirez Asset Management Inc.

Ramirez Asset Management Inc. lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 25.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300 shares of the medical research company’s stock after selling 100 shares during the period. Ramirez Asset Management Inc.’s holdings in Natera were worth $51,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Bank of Jackson Hole Trust acquired a new stake in Natera in the 1st quarter valued at about $29,000. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter valued at about $33,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Natera in the 2nd quarter valued at about $36,000. Rakuten Securities Inc. raised its position in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 119 shares in the last quarter. Finally, TCTC Holdings LLC raised its position in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $132.89, for a total transaction of $398,670.00. Following the transaction, the insider owned 123,059 shares in the company, valued at $16,353,310.51. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NTRA. Barclays reaffirmed an “overweight” rating and issued a $210.00 price target (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Wednesday. Cowen reiterated a “buy” rating on shares of Natera in a report on Friday, August 8th. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $192.88.

Natera Stock Down 2.2%

NASDAQ:NTRA opened at $169.27 on Friday. The stock’s 50 day moving average price is $164.58 and its 200 day moving average price is $157.22. The company has a market capitalization of $23.23 billion, a PE ratio of -88.62 and a beta of 1.74. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.